Roche and Merck & Co have got their respective immunotherapies Tecentriq and Keytruda approved in bladder cancer – but ... who are jointly developing enfortumab vedotin, an antibody-drug ...

Seattle Genetics and Astellas have filed their antibody-drug conjugate enfortumab vedotin with the US drug regulator for advanced bladder cancer, after failure of chemotherapy and immunotherapy.

Enfortumab vedotin showed a robust disease control rate in patients with urothelial cancer outside of a clinical ... control rate in patients with advanced urothelial carcinoma (aUC) outside ...

3月28日，安斯泰来制药集团宣布，中国国家药品监督管理局（NMPA）药品审评中心（CDE）已于2024年3月27日受理enfortumab vedotin与pembrolizumab（帕博利珠单 ...

Japan’s MHLF approves Padcev with Keytruda for first-line treatment of radically unresectable urothelial carcinoma: Tokyo Wednesday, September 25, 2024, 11:00 Hrs [IST] Astellas ...

A new combination of cancer ... enfortumab vedotin and the immunotherapy pembrolizumab, administered through IV infusions, cut the risk of disease progression or death by 55% in patients with ...

Medscape Medical News, March 11, 2020 GUCS 2020 Unprecedented Response Rate in Advanced Bladder Cancer The combination of enfortumab vedotin plus pembrolizumab as a first-line treatment for ...

[1] Powles T, et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial ... August 2024. [4] National Cancer Institute. Cancer stat facts: bladder cancer. Available at: https ...

The NIAGARA trial with Imfinzi is the first study to show an OS benefit in both the neoadjuvant and adjuvant settings.

Opens in a new tab or window In the U.S., the economic burden associated with the latest first-line treatments for locally advanced or ... well as the use of enfortumab vedotin plus pembrolizumab ...

GUCS 2024 ctDNA Clearance Predicts Relapse Risk in Urothelial Cancer ... advanced non-small cell lung cancer (NSCLC)... Reuters Health Information, January 22, 2024 Alert FDA OKs Enfortumab ...